eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.…
EXoZymes Inc (EXOZ) (Q3 2026) Earnings Call Highlights: Curia Manufacturing Deal, DOE Grant and ...
eXoZymes (NASDAQ: EXOZ) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 32 employees.
The shares were at 2.905 USD on 20 November 2026, down 82.0% over 52 weeks. Its 52-week range is 2.840 USD to 16.90 USD: the price is 82.8% below the high and 2.3% above the low.
Its market capitalisation is 27.42M USD.
eXoZymes reports return on equity of -269.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.57M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.